Mapping the immune system could lead to the creation of drugs that help our bodies win the fight against cancer and other diseases. That’s the big idea behind immunotherapy. The problem: the immune system is incredibly complex.
Enter Immunai, a biotech company that’s using cutting-edge genomics & ML technology to map the human immune system and develop new immunotherapies against cancer and autoimmune diseases.
On this episode of NVIDIA’s AI Podcast, host Noah Kravitz spoke with Luis Voloch, co-founder and CTO of Immunai, about tackling the challenges of the immune system with a machine learning and data science mindset.
It may seem intuitive that AI and deep learning can speed up workflows — including novel drug discovery, a typically years-long and several-billion-dollar endeavor. However, there is a dearth of recent research reviewing how accelerated computing can impact the process. Professors Artem Cherkasov and Olexandr Isayev discuss how GPUs can help democratize drug discovery.
Is it possible to manipulate things with your mind? Possibly. University of Minnesota postdoctoral researcher Jules Anh Tuan Nguyen discusses allowing amputees to control their prosthetic limbs with their thoughts, using neural decoders and deep learning.
Studying endangered species can be difficult, as they’re elusive, and the act of observing them can disrupt their lives. Sifei Liu, a senior research scientist at NVIDIA, discusses how scientists can avoid these pitfalls by studying AI-generated 3D representations of these endangered species.
You can now listen to the AI Podcast through Amazon Music.
Also get the AI Podcast through iTunes, Google Podcasts, Google Play, Castbox, DoggCatcher, Overcast, PlayerFM, Pocket Casts, Podbay, PodBean, PodCruncher, PodKicker, Soundcloud, Spotify, Stitcher and TuneIn.
The post Immunai Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs appeared first on NVIDIA Blog.
Depois de gerar vários prompts e combinar vários LoRas, tentei tudo o que você pode…
Here is the number that defines the current state of things:
Today, Amazon SageMaker AI introduces OpenAI-compatible API support for real-time inference endpoints. If you use…
LLMs have become more powerful at smaller sizes, but deploying them to edge devices like…
The rocket company has set aside more than $500 million for potential litigation losses, in…
Patrick Traynor, Ph.D., has questions. When the professor and interim chair of the University of…